Inovio Pharmaceuticals Inc (INO)

[KR_redondo]

BIO Investor Forum October 8-9, 2013


Therapeutic Workshops


The Ultimate Rejection: Fighting Cancer with Immunotherapy

Tuesday, October 8, 2013, 10:30 a.m. - 11:25 a.m., Twin Peaks North/South

Enhancing the human body’s natural immune system to stimulate response and produce effective treatments has long been thought to be a promising a approach to fighting cancer and other debilitating illnesses. By leveraging the body’s own ability to fight disease, immunotherapeutics effectively “work smarter” than traditional treatments. With pharma companies wiling to pay top dollars to develop these drugs, the field of cancer immunotherapy has piqued the interest of investors as well. This year’s ASCO spotlighted lung cancer as the newest target for immunotherapy. Hear experts from companies at the forefront of this exciting field discuss what lies ahead.

Moderator

Joseph Pantginis, PhD, Senior Research Analyst, ROTH Capital Partners
Panelists

James B. Breitmeyer, MD, PhD, Division President Cancer Vaccines, Executive Vice President, Bavarian Nordic A/S

Lawrence Fong, MD, Associate Professor, Department of Medicine (Hematology/Oncology), UCSF Medical Center

Paul G. Higham CEO immatics biotechnologies GmbH

J. Joseph Kim, PhD, President, CEO & Director, Inovio Pharmaceuticals




http://www.bio.org/events/conferences/participating-investors